Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches.

PubWeight™: 1.16‹?› | Rank: Top 10%

🔗 View Article (PMID 15221580)

Published in Support Care Cancer on June 19, 2004

Authors

Paul J Hesketh1, Diane Batchelor, Mitch Golant, Gary H Lyman, Nelson Rhodes, Denise Yardley

Author Affiliations

1: Division of Hematology/Oncology, Caritas St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA, USA. phesketh@massmed.org

Articles citing this

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA (2017) 1.09

Prevention of chemotherapy-induced alopecia in rodent models. Cell Stress Chaperones (2008) 1.06

Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain. Int J Cancer (2012) 1.02

Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy. Am J Pathol (2007) 0.92

Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. J Biol Chem (2013) 0.91

Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist (2013) 0.88

Assessing the body image: relevance, application and instruments for oncological settings. Support Care Cancer (2011) 0.88

Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Support Care Cancer (2013) 0.87

Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies. Aesthetic Plast Surg (2014) 0.86

A novel rat model for chemotherapy-induced alopecia. Clin Exp Dermatol (2012) 0.84

Effects of alopecia on body image and quality of life of Turkish cancer women with or without headscarf. Support Care Cancer (2011) 0.84

Functioning and health in patients with cancer on home-parenteral nutrition: a qualitative study. Health Qual Life Outcomes (2010) 0.80

Testing chemotherapeutic agents in the feather follicle identifies a selective blockade of cell proliferation and a key role for sonic hedgehog signaling in chemotherapy-induced tissue damage. J Invest Dermatol (2014) 0.79

Familiarity, opinions, experiences and knowledge about scalp cooling: a Dutch survey among breast cancer patients and oncological professionals. Asia Pac J Oncol Nurs (2016) 0.78

The α-lipoic acid derivative sodium zinc dihydrolipoylhistidinate reduces chemotherapy-induced alopecia in a rat model: a pilot study. Surg Today (2011) 0.77

Safety and Efficacy of Bimatoprost for Eyelash Growth in Postchemotherapy Subjects. J Clin Aesthet Dermatol (2015) 0.75

Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in female cancer patients. Curr Oncol (2016) 0.75

Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials. J Clin Aesthet Dermatol (2015) 0.75

Hair camouflage: A comprehensive review. Int J Womens Dermatol (2017) 0.75

Determination of the most effective cooling temperature for the prevention of chemotherapy-induced alopecia. Mol Clin Oncol (2013) 0.75

Hair camouflage: A comprehensive review. Int J Womens Dermatol (2016) 0.75

Articles cited by this

Impact of Event Scale: a measure of subjective stress. Psychosom Med (1979) 21.82

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol (1993) 18.75

Information and participation preferences among cancer patients. Ann Intern Med (1980) 11.05

The biology of hair follicles. N Engl J Med (1999) 4.46

On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol (1983) 4.35

Electronic support groups for breast carcinoma: a clinical trial of effectiveness. Cancer (2003) 2.93

The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol (1997) 2.68

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol (1996) 2.03

Prevention of doxorubicin-induced hair loss with scalp hypothermia. N Engl J Med (1979) 1.94

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer (1997) 1.88

Changing patient perceptions of the side effects of cancer chemotherapy. Cancer (2002) 1.78

Towards a molecular understanding of hair loss and its treatment. Trends Mol Med (2001) 1.55

Psychological sequelae and alopecia among women with cancer. Cancer Pract (2002) 1.42

p53 is essential for chemotherapy-induced hair loss. Cancer Res (2000) 1.29

Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. Am J Pathol (1997) 1.17

Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer (2003) 1.12

Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer (2000) 1.08

Hair and cancer chemotherapy: consequences and nursing care--a literature study. Eur J Cancer Care (Engl) (2001) 1.03

Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res (1996) 1.02

Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer (1997) 1.00

A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol (1996) 0.99

A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist. J Invest Dermatol (2001) 0.91

Protection from chemotherapy-induced alopecia by 1,25-dihydroxyvitamin D3. Cancer Res (1992) 0.89

Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology (2002) 0.88

Hair follicle apoptosis and Bcl-2. J Investig Dermatol Symp Proc (1999) 0.87

Alopecia and cytotoxic drugs. Br Med J (1966) 0.85

Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia. Ann Oncol (1994) 0.85

Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy. Support Care Cancer (2002) 0.83

Scalp cooling by cold air for the prevention of chemotherapy-induced alopecia. Neth J Med (1990) 0.83

Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer. Eur J Cancer (1990) 0.82

Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia. Eur J Pharmacol (2001) 0.82

A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. Anticancer Drugs (1999) 0.81

The psychosocial aspects of breast cancer. Nurse Pract Forum (1999) 0.81

Behavioural interventions and psychological aspects of care during chemotherapy. Eur J Cancer (1992) 0.81

Scalp hypothermia in the prevention of chemotherapy-induced alopecia. Acta Radiol Oncol (1985) 0.80

The symptom experience of alopecia. Semin Oncol Nurs (1995) 0.79

Protection from chemotherapy-induced alopecia by docosahexaenoic acid. Lipids (1999) 0.79

Protection against chemotherapy-induced alopecia by cyclosporin A in the newborn rat animal model. Dermatology (1995) 0.79

A study of patients' experiences of side-effects associated with chemotherapy: pilot stage report. Int J Nurs Stud (1995) 0.78

Scalp tourniquet in the prevention of chemotherapy-induced alopecia. N Engl J Med (1978) 0.77

A narrative study of chemotherapy-induced alopecia. Oncol Nurs Forum (1999) 0.77

Chemotherapy-induced hair loss. Nurs Stand (1991) 0.77

Protection from chemotherapy-induced alopecia. Med Pediatr Oncol (1991) 0.76

Nursing issues and management in chemotherapy-induced alopecia. Oncol Nurs Forum (1989) 0.76

Ineffectiveness of scalp hypothermia in the prevention of alopecia in patients treated with doxorubicin and cisplatin combinations. Cancer Treat Rep (1984) 0.76

Preventing chemotherapy-induced alopecia in cancer patients: is scalp cooling worthwhile? J Adv Nurs (1987) 0.76

Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. Int J Dermatol (1995) 0.75

Evaluation of a patient file folder to improve the dissemination of written information materials for cancer patients. Cancer (1998) 0.75

Patients education: self-care guides. Semin Oncol Nurs (1995) 0.75

The effects of using Chemocap on occurrence of chemotherapy-induced alopecia. Oncol Nurs Forum (1983) 0.75

Articles by these authors

(truncated to the top 100)

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26

Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03

Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42

Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06

American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03

Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86

Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27

Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15

Electronic support groups for breast carcinoma: a clinical trial of effectiveness. Cancer (2003) 2.93

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res (2009) 2.90

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73

Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer (2011) 2.67

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol (2012) 2.43

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37

Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer (2009) 2.35

Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25

Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20

Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol (2006) 2.17

Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13

The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12

Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02

Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol (2007) 1.92

Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med (2008) 1.85

American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol (2008) 1.75

Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res (2010) 1.66

Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw (2008) 1.65

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer (2007) 1.54

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem (2008) 1.41

Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care (2008) 1.39

Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39

Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol (2005) 1.38

Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol (2008) 1.27

Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med (2014) 1.27

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat (2006) 1.25

Undertreatment of cancer patients with chemotherapy is a global concern. J Oncol Pract (2008) 1.23

Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.23

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol (2004) 1.18

Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health (2008) 1.14

Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw (2011) 1.14

Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw (2003) 1.14

Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol (2014) 1.13

Myeloid growth factors. J Natl Compr Canc Netw (2013) 1.13

American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol (2012) 1.12

Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol (2011) 1.12

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer (2007) 1.11

ASCO Clinical Practice Guidelines: Past, Present and Future. J Oncol Pract (2008) 1.10

Costs associated with febrile neutropenia in the US. Pharmacoeconomics (2012) 1.06

Palliative Care Integration Project (PCIP) quality improvement strategy evaluation. J Pain Symptom Manage (2008) 1.06

Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol (2012) 1.04

Myeloid growth factors. J Natl Compr Canc Netw (2011) 1.03

Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med (2014) 1.03

Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med (2012) 1.03

Antiemetics: american society of clinical oncology clinical practice guideline update. J Oncol Pract (2011) 1.02

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer (2009) 1.02

Mood disturbance in community cancer support groups. The role of emotional suppression and fighting spirit. J Psychosom Res (2003) 0.98

Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J Natl Cancer Inst (2013) 0.98

Metabolic perturbance in autism spectrum disorders: a metabolomics study. J Proteome Res (2012) 0.97

The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw (2008) 0.96

Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat (2012) 0.96

Breast cancer screening with mammography. Curr Oncol Rep (2011) 0.95

Myeloid growth factors. J Natl Compr Canc Netw (2009) 0.94

Incidence-based cost-of-illness model for metastatic breast cancer in the United States. Int J Technol Assess Health Care (2012) 0.94

Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma (2006) 0.93

Hemopoiesis and aging. Cancer Treat Res (2005) 0.93

Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract (2013) 0.93

Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol (2009) 0.92

The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther (2004) 0.90

Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest. J Thorac Oncol (2011) 0.90

Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health (2008) 0.89

Self-report and linguistic indicators of emotional expression in narratives as predictors of adjustment to cancer. J Behav Med (2006) 0.89

Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst (2011) 0.89

Standard versus prosocial online support groups for distressed breast cancer survivors: a randomized controlled trial. BMC Cancer (2011) 0.89

Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecol Oncol (2012) 0.88

Time is money for both the healthy and the sick. Med Care (2005) 0.88

First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist (2013) 0.88

Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg (2011) 0.87

A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value Health (2012) 0.87

Will biosimilars gain momentum? J Natl Compr Canc Netw (2013) 0.87

Facilitating online support groups for cancer patients: the learning experience of psycho-oncology clinicians. Psychooncology (2010) 0.87

Ductal carcinoma in situ: a review of recent advances. Curr Opin Obstet Gynecol (2007) 0.87

Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. Med Care (2011) 0.87

Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Res Treat (2011) 0.87

Screening mammography at 40-49 years: regret or no regret? Lancet (2006) 0.86

Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest (2009) 0.86

Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev (2006) 0.85

Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med (2004) 0.85

Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines? J Oncol Pract (2011) 0.85

Availability of experimental therapy outside oncology randomized clinical trials in the United States. J Clin Oncol (2010) 0.85

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. J Hematol Oncol (2010) 0.84

Online support groups for Parkinson's patients: a pilot study of effectiveness. Soc Work Health Care (2005) 0.84